| Q34687036 | A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma |
| Q36335477 | Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts |
| Q38869809 | An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. |
| Q28543862 | An ex vivo model for anti-angiogenic drug testing on intact microvascular networks |
| Q36636633 | Anti-VEGF therapy: a new approach to colorectal cancer therapy |
| Q37230783 | Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent |
| Q37955304 | Anti-angiogenic therapy: concept to clinic |
| Q33665288 | Antiangiogenetic Effects of 4 Varieties of Grapes In Vitro |
| Q37883011 | Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? |
| Q38847330 | Assessment of tumor response to radiation and vascular targeting therapy in mice using quantitative ultrasound spectroscopy |
| Q37098098 | Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib |
| Q45934010 | Characteristic genotypes of vascular endothelial growth factor are susceptible to ascites in patients with cirrhosis. |
| Q54347154 | Circulating tumor-associated neutrophils (cTAN) contribute to circulating tumor cell survival by suppressing peripheral leukocyte activation. |
| Q36192000 | Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials |
| Q39398836 | Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines |
| Q36965629 | Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03). |
| Q35597086 | Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy |
| Q36625228 | Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors |
| Q37578218 | Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies |
| Q36611473 | Digestive tract hemorrhage due to complications with gastrointestinal stromal tumor treated with sunitinib: A case report |
| Q44760028 | Dose-dependent response of tumor vasculature to radiation therapy in combination with Sunitinib depicted by three-dimensional high-frequency power Doppler ultrasound |
| Q37357314 | Early development of sunitinib in hepatocellular carcinoma |
| Q34645665 | Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial |
| Q28268831 | Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial |
| Q34656707 | Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience. |
| Q41885351 | Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate |
| Q47673133 | Gastrointestinal Malignancy: Genetic Implications to Clinical Applications |
| Q37218711 | Heterogeneity of kinase inhibitor resistance mechanisms in GIST |
| Q59430751 | Hypertension in cancer patients treated with anti-angiogenic based regimens |
| Q35634179 | Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy |
| Q37847051 | Immunomodulatory effects of anti-angiogenic drugs |
| Q49592831 | Immunotherapeutic Targeting of Tumor-Associated Blood Vessels |
| Q37576843 | Impact of rechallenge with imatinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib and sunitinib. |
| Q33384849 | Improved bone healing by angiogenic factor-enriched platelet-rich plasma and its synergistic enhancement by bone morphogenetic protein-2 |
| Q33738607 | In vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors |
| Q33552232 | Indolyl-quinuclidinols inhibit ENOX activity and endothelial cell morphogenesis while enhancing radiation-mediated control of tumor vasculature |
| Q39880781 | Inhibition of cell proliferation, vascular endothelial growth factor and tumor growth by albendazole |
| Q37673218 | Inostamycin prevents malignant phenotype of cancer: inhibition of phosphatidylinositol synthesis provides a therapeutic advantage for head and neck squamous cell carcinoma |
| Q37799829 | Latest developments in targeted therapy for hepatocellular carcinoma. |
| Q36906667 | Molecular basis for sunitinib efficacy and future clinical development |
| Q36293536 | Molecular research directions in the management of gastrointestinal stromal tumors |
| Q38389986 | Multi-targeted tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: an era of individualized therapy |
| Q41554303 | One-day treatment of small molecule 8-bromo-cyclic AMP analogue induces cell-based VEGF production for in vitro angiogenesis and osteoblastic differentiation |
| Q34226634 | PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines |
| Q38099390 | Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors |
| Q37190323 | Phase I trial of concurrent sunitinib and radiation therapy as preoperative treatment for soft tissue sarcoma |
| Q38176966 | Regorafenib for treatment of advanced gastrointestinal stromal tumors. |
| Q35519994 | Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program |
| Q91979492 | Relationship between efficacy of sunitinib and KIT mutation of patients with advanced gastrointestinal stromal tumors after failure of imatinib: A systematic review |
| Q37254387 | Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis |
| Q46957688 | Sunitinib |
| Q37301234 | Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma |
| Q37797460 | Sunitinib for Metastatic Renal Cell Carcinoma |
| Q34884647 | Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance |
| Q37960905 | Sunitinib for advanced pancreatic neuroendocrine tumors. |
| Q37307562 | Sunitinib for advanced renal cell cancer |
| Q35871185 | Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib |
| Q39952447 | Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential |
| Q28072057 | Sunitinib in the treatment of metastatic renal cell carcinoma |
| Q34380617 | Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells |
| Q37226817 | Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis |
| Q36858232 | Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor |
| Q39889569 | Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase |
| Q54353589 | Sunitinib: from charge-density studies to interaction with proteins. |
| Q44500706 | Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors |
| Q28066499 | Sunitinib: the antiangiogenic effects and beyond |
| Q37905587 | Targeted therapy in renal cancer |
| Q33920350 | Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply. |
| Q91789075 | The Use of Molecular Subtypes for Precision Therapy of Recurrent and Metastatic Gastrointestinal Stromal Tumor |
| Q38144166 | The potential of sunitinib as a therapy in ovarian cancer |
| Q37521316 | The role of antiangiogenesis therapy: bevacizumab and beyond |
| Q35975387 | The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors |
| Q48634468 | The use of sunitinib in renal cell carcinoma: where are we now? |
| Q54559288 | Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma. |
| Q38874224 | VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments. |
| Q54548367 | [Current status and future direction of multi-targeted drugs in the era of personalized therapy--overview of advances in multi-targeted therapy in non-small cell lung cancer]. |